Theratech!
Seite 1 von 1 Neuester Beitrag: 25.04.21 01:46 | ||||
| Eröffnet am: | 27.02.15 13:07 | von: iwanooze | Anzahl Beiträge: | 20 |
| Neuester Beitrag: | 25.04.21 01:46 | von: Inesnodta | Leser gesamt: | 8.075 |
| Forum: | Hot-Stocks | Leser heute: | 2 | |
| Bewertet mit: |  | |||
Theratechnologies Announces Commercialization Agreement for EGRIFTA(TM) (Tesamorelin for Injection) in Europe
MONTREAL, CANADA, Feb 27, 2015 (Marketwired via COMTEX) -- Theratechnologies Inc. (TH) is pleased to announce that it has concluded an agreement with AOP Orphan Pharmaceuticals AG (AOP) for the distribution and commercialization of EGRIFTA(TM) in several European countries.
Under the terms of the agreement, AOP will be responsible to conduct all regulatory activities to obtain marketing authorizations for EGRIFTA(TM) on a country-by-country basis in the territory. Prior to receiving such marketing authorizations, AOP intends to distribute EGRIFTA(TM) in the territory through Named Patient Sales Programs.
Theratechnologies will be responsible for the manufacture of EGRIFTA(TM) and its supply to AOP at a predetermined transfer price. Moreover, AOP will pay royalties on net sales of EGRIFTA(TM) over a certain price level. The AOP agreement further provides for a milestone payment upon obtaining marketing authorizations, pricing and reimbursement approvals in countries totalling a certain number of inhabitants, as well as milestone payments upon reaching certain levels of cumulative net sales of EGRIFTA(TM) in the territory. An upfront payment of 150,000 Euros is associated with the execution of the Agreement. Including that upfront payment, milestone payments could potentially reach a combined total of three million Euros. The term of the Agreement varies on a country-by-country basis and extends for seven years from the first sales of EGRIFTA(TM) in each country or February 25, 2025, whichever is later.
"We are thrilled of our association with AOP. They have a proven track record at being successful in commercializing niche products and this agreement gives us a great opportunity to enter the European market over a short time frame. We had set in our 2015 business plan to find a partner to distribute EGRIFTA(TM) in Europe. We are very pleased to have reached that objective. This is yet another significant step that aims to bring shareholder value through the realization of the full commercial potential of EGRIFTA(TM)," said Luc Tanguay, President and CEO, Theratechnologies Inc.
The countries covered by the distribution and licencing agreement includes Austria, Albania, Belarus, Belgium, Bosnia, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Kazakhstan, Latvia, Lithuania, Luxembourg, Macedonia, Netherlands, Norway, Poland, Romania, Russian Federation, Serbia, Slovak Republic, Slovenia, Sweden, Switzerland, Ukraine, and the United Kingdom.
AOP Orphan Pharmaceuticals is a privately-owned company based in Vienna, Austria. Founded in 1996, it specializes in rare diseases through the development, distribution and commercialization of innovative therapies. It currently markets 15 drugs in various European countries.
MONTREAL, CANADA, Feb 27, 2015 (Marketwired via COMTEX) -- Theratechnologies Inc. (TH) is pleased to announce that it has concluded an agreement with AOP Orphan Pharmaceuticals AG (AOP) for the distribution and commercialization of EGRIFTA(TM) in several European countries.
Under the terms of the agreement, AOP will be responsible to conduct all regulatory activities to obtain marketing authorizations for EGRIFTA(TM) on a country-by-country basis in the territory. Prior to receiving such marketing authorizations, AOP intends to distribute EGRIFTA(TM) in the territory through Named Patient Sales Programs.
Theratechnologies will be responsible for the manufacture of EGRIFTA(TM) and its supply to AOP at a predetermined transfer price. Moreover, AOP will pay royalties on net sales of EGRIFTA(TM) over a certain price level. The AOP agreement further provides for a milestone payment upon obtaining marketing authorizations, pricing and reimbursement approvals in countries totalling a certain number of inhabitants, as well as milestone payments upon reaching certain levels of cumulative net sales of EGRIFTA(TM) in the territory. An upfront payment of 150,000 Euros is associated with the execution of the Agreement. Including that upfront payment, milestone payments could potentially reach a combined total of three million Euros. The term of the Agreement varies on a country-by-country basis and extends for seven years from the first sales of EGRIFTA(TM) in each country or February 25, 2025, whichever is later.
"We are thrilled of our association with AOP. They have a proven track record at being successful in commercializing niche products and this agreement gives us a great opportunity to enter the European market over a short time frame. We had set in our 2015 business plan to find a partner to distribute EGRIFTA(TM) in Europe. We are very pleased to have reached that objective. This is yet another significant step that aims to bring shareholder value through the realization of the full commercial potential of EGRIFTA(TM)," said Luc Tanguay, President and CEO, Theratechnologies Inc.
The countries covered by the distribution and licencing agreement includes Austria, Albania, Belarus, Belgium, Bosnia, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Kazakhstan, Latvia, Lithuania, Luxembourg, Macedonia, Netherlands, Norway, Poland, Romania, Russian Federation, Serbia, Slovak Republic, Slovenia, Sweden, Switzerland, Ukraine, and the United Kingdom.
AOP Orphan Pharmaceuticals is a privately-owned company based in Vienna, Austria. Founded in 1996, it specializes in rare diseases through the development, distribution and commercialization of innovative therapies. It currently markets 15 drugs in various European countries.
EGRIFTA!!
in usa seit september!
http://www.theratech.com/sites/default/files/...esuming_v12_clean.pdf
nun europa!
The countries covered by the distribution and licencing agreement includes Austria, Albania, Belarus, Belgium, Bosnia, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Kazakhstan, Latvia, Lithuania, Luxembourg, Macedonia, Netherlands, Norway, Poland, Romania, Russian Federation, Serbia, Slovak Republic, Slovenia, Sweden, Switzerland, Ukraine, and the United Kingdom.
in usa seit september!
http://www.theratech.com/sites/default/files/...esuming_v12_clean.pdf
nun europa!
The countries covered by the distribution and licencing agreement includes Austria, Albania, Belarus, Belgium, Bosnia, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Kazakhstan, Latvia, Lithuania, Luxembourg, Macedonia, Netherlands, Norway, Poland, Romania, Russian Federation, Serbia, Slovak Republic, Slovenia, Sweden, Switzerland, Ukraine, and the United Kingdom.
https://www.google.com/...ce?q=TSE%3ATH&ei=pWjwVLOZHKOZwwPMpYGQCA
https://www.google.com/...CMKTS%3ATHERF&ei=LI3wVLDkA8r-wwPh14DoAQ
http://www.boerse-frankfurt.de/de/aktien/...nologies+inc+CA88338H1001
nur leider wenig volumen.
Outstanding shares 61,1 mill
hatten sogar
"Theratechnologies Inc's quarterly shares outstanding declined from May. 2014 (61.03 Mil) to Aug. 2014 (61.01 Mil). It means Theratechnologies Inc bought back shares from May. 2014 to Aug. 2014 "
https://www.google.com/...CMKTS%3ATHERF&ei=LI3wVLDkA8r-wwPh14DoAQ
http://www.boerse-frankfurt.de/de/aktien/...nologies+inc+CA88338H1001
nur leider wenig volumen.
Outstanding shares 61,1 mill
hatten sogar
"Theratechnologies Inc's quarterly shares outstanding declined from May. 2014 (61.03 Mil) to Aug. 2014 (61.01 Mil). It means Theratechnologies Inc bought back shares from May. 2014 to Aug. 2014 "
Klasse Job ;)
Optionen
| Boardmail an "Global-Invest" |
Wertpapier: Theratechnologies |
Theratechnologies Inc. is a Canada-based pharmaceutical company, which addresses unmet medical needs in metabolic disorders. The Company’s product EGRIFTA(TSE:TH), approved by the United States Food and Drug Administration helps to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA (tesamorelin for injection) was also approved by Health Canada for the treatment of excess visceral adipose tissue (VAT) in treatment-experienced adult HIV-infected patients. EGRIFTA is an injectable prescription medicine contains a growth hormone-releasing factor (GRF).
Theratechnologies to raise $9.6-million at $2.40
2015-07-23 17:42 ET - News Release
Mr. Denis Boucher reports
THERATECHNOLOGIES ANNOUNCES $9,600,000 FIRM OFFERING OF UNITS AND FILING OF PRELIMINARY SHORT FORM PROSPECTUS
Theratechnologies Inc. has filed and obtained a receipt for a preliminary short form prospectus and has entered into a firm underwriting agreement with a syndicate of underwriters led by Euro Pacific Canada Inc. and including Mackie Research Capital Corporation in connection with an offering of four million units at a price of $2.40 per unit for gross proceeds of $9.6-million. Each unit shall consist of one common share and one-half of a common share purchase warrant exercisable for a period of 24 months from the closing date of the offering at an exercise price of $3.00.
Theratechnologies has also granted the underwriters an option to purchase up to 600,000 additional units, representing 15 per cent of the number of units offered hereby, at the same price and on the same terms and conditions as the offering, exercisable in whole or in part at any time not later than the 30th day following the closing of the offering to cover any overallotments and for market stabilization purposes.
Theratechnologies intends to use the net proceeds of the offering for working capital purposes and for general corporate purposes, including the commercialization activities relating to the company's product, Egrifta. Pursuant to the offering, the units will be offered in all provinces of Canada by way of a short form prospectus and in the U.S. on a private placement basis pursuant to exemptions from registration requirements. Closing of the offering is expected to occur on or about Aug. 7, 2015, and is subject to certain customary conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Toronto Stock Exchange.
2015-07-23 17:42 ET - News Release
Mr. Denis Boucher reports
THERATECHNOLOGIES ANNOUNCES $9,600,000 FIRM OFFERING OF UNITS AND FILING OF PRELIMINARY SHORT FORM PROSPECTUS
Theratechnologies Inc. has filed and obtained a receipt for a preliminary short form prospectus and has entered into a firm underwriting agreement with a syndicate of underwriters led by Euro Pacific Canada Inc. and including Mackie Research Capital Corporation in connection with an offering of four million units at a price of $2.40 per unit for gross proceeds of $9.6-million. Each unit shall consist of one common share and one-half of a common share purchase warrant exercisable for a period of 24 months from the closing date of the offering at an exercise price of $3.00.
Theratechnologies has also granted the underwriters an option to purchase up to 600,000 additional units, representing 15 per cent of the number of units offered hereby, at the same price and on the same terms and conditions as the offering, exercisable in whole or in part at any time not later than the 30th day following the closing of the offering to cover any overallotments and for market stabilization purposes.
Theratechnologies intends to use the net proceeds of the offering for working capital purposes and for general corporate purposes, including the commercialization activities relating to the company's product, Egrifta. Pursuant to the offering, the units will be offered in all provinces of Canada by way of a short form prospectus and in the U.S. on a private placement basis pursuant to exemptions from registration requirements. Closing of the offering is expected to occur on or about Aug. 7, 2015, and is subject to certain customary conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Toronto Stock Exchange.
Moderation
Zeitpunkt: 23.04.21 15:14
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Spam
Zeitpunkt: 23.04.21 15:14
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Spam